Organigram Strikes $401M Deal for Aurora, Sidelining Curaleaf's Hostile Bid

A major twist in the cannabis M&A world landed on Tuesday, when Organigram Global Inc. announced plans to acquire Aurora Cannabis Inc. in a transaction valued at roughly $401 million. The agreement effectively puts an end to the hostile takeover bid that Curaleaf Holdings, Inc. had been pursuing for Aurora, which means the competition for the company has now been settled in Organigram's favor.

The price on the table is $5.57 per Aurora share. That works out to a 93% premium over Aurora's unaffected share price on August 10. In deal-speak, the unaffected price is where a stock was trading before takeover activity started moving it, so it's meant to show what the company was worth in the market before outside interest kicked in. A premium that large signals that Aurora shareholders are being offered far more than the stock fetched before the bidding began. The announcement also cites a second premium figure of 21%, though the full context for that number wasn't included in the summary we reviewed.

The outcome matters because a hostile bid is an unsolicited push to take over a company without the backing of its leadership. Curaleaf's attempt put pressure on Aurora's board, and a friendly agreement with Organigram changes the direction of the whole situation. Instead of being absorbed through a contested offer, Aurora now has a negotiated path forward with a different buyer.

For anyone who follows the business side of cannabis, this is another sign that consolidation is still reshaping the industry. Large licensed producers keep looking for scale, stronger market positions, and ways to cut through a crowded field. Whether this deal changes what shows up on shelves or in product lineups is still unknown, and the details of closing, approvals, and integration will matter. For now, the headline is simple: Organigram has beaten Curaleaf to the finish line for Aurora, and shareholders are being offered a hefty premium to go along with it.